Announcements Trials
Browse Landscape

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 179Observational 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Blood Specimen Collection 135Surveys and Questionnaires 132Specimen Handling 57Observation 55Radiotherapy 43Interviews as Topic 35Surgical Procedures, Operative 31Biopsy 30Drug Therapy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Immune Checkpoint Inhibitors 18Watchful Waiting 18Standard of Care 17Therapeutics 17Immunotherapy 16Magnetic Resonance Imaging 16trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13palbociclib 13Radiosurgery 12enzalutamide 12Focus Groups 11Hematologic Tests 11apalutamide 11darolutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Fulvestrant × 1 year × Clear all
NCT07347600 2026-05-18

reaINAVO

Hoffmann-La Roche

Recruiting
500 enrolled
Breast

Breast Neoplasms

NCT05022342 2026-02-23

SPEAR

Novartis

Completed
595 enrolled
Breast

Breast Neoplasms

NCT04967248 2025-12-04

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Novartis

Terminated
4 enrolled
Breast

Breast Neoplasms

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

Pfizer

Completed
1,772 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡